News Search Results
Feb 05, 2026, 08:00 ET Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
predicted human efficacious dose, with high potential in multiple indications including autoimmune and chronic cardiometabolic diseases with no obvious CNS (central nervous system) related toxicity observed in preclinical studies.HONG KONG, Feb.
More news about: Insilico Medicine
Feb 04, 2026, 08:44 ET Allergy Research Group Announces Peer-Reviewed Publication Advancing Thyroid and Endocrine Integration Science
International Journal of Molecular Sciences. The paper, "Energy Allocation Resilience and Endocrine Integration," is led by Dr. Corey Schuler, DC, MS, CNS, LN, Director of Medical Affairs at Allergy Research Group, with contributions from members of ARG's Medical Affairs Team and Scientific Advisory Board,
More news about: Allergy Research Group
Feb 03, 2026, 10:47 ET Cognision Launches Cognision360™: A Unified Platform Transforming Neurobiomarker Acquisition, Processing, and Analysis in CNS Clinical Trials
data streams into a single, standardized system—addressing one of the pharmaceutical industry's most persistent challenges in central nervous system (CNS) drug development.
More news about: Cognision
Feb 02, 2026, 08:25 ET Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio
disorders.BT-409 is an orally administered small-molecule designed to selectively inhibit the NLRP3 inflammasome with demonstrated central nervous system (CNS) penetration. Preclinical studies support its potential to directly modulate neuroinflammation within the brain, differentiating it from peripherally
More news about: Mwyngil Therapeutics
Jan 29, 2026, 19:01 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Jan 29, 2026, 16:46 ET Myosin Therapeutics Invited to Present at Biocom California's Global Partnering & Investor Conference
TherapeuticsMyosin Therapeutics is a biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program, MT-125, is being developed for glioblastoma as the lead indication within
More news about: Myosin Therapeutics Inc.
Jan 29, 2026, 10:06 ET Sprout Pharmaceuticals' Addyi® (flibanserin) Named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards
increase the risk of hypotension and syncope.Central Nervous System (CNS) Depression (e.g., Somnolence, Sedation): Can occur with ADDYI alone and is exacerbated by other CNS depressants. The risk of CNS depression is also increased if ADDYI is taken during waking hours. Patients should
More news about: Sprout Pharmaceuticals
Jan 29, 2026, 07:00 ET Corero Network Security Secures Two Tier-1 APAC Telecommunications Wins
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced two significant wins
More news about: Corero Network Security
Jan 29, 2026, 07:00 ET Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
includes peripheral TYK2 (JH2) inhibitor for moderate-to-severe plaque psoriasis currently in Phase III trials, and central TYK2 (JH2) inhibitor for CNS diseases in Phase I trials. With a rich and innovative pipeline targeting numerous current refractory and incurable diseases, the company is dedicated
More news about: Zhejiang Wenda Pharma Technology Co., Ltd.
Jan 29, 2026, 04:00 ET LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress
diverse array of therapeutic modalities and technologies, in particular areas with significant unmet needs such as autoimmune diseases, fibrosis and CNS disorders.GlycoEra AG's $130 million Series B: LifeArc Ventures joined Novo Holdings, Catalio Capital Management, QIA,
More news about: LifeArc
Jan 28, 2026, 22:31 ET Corero Network Security Mendapatkan Dua Kontrak Dengan Perusahaan Telekomunikasi Terkemuka di Asia Pasifik
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah pemimpin yang diakui di bidang DDoS protection maupun ketersediaan layanan di waktu nyata dan dapat disesuaikan. Hari ini Corero
More news about: Corero Network Security
Jan 28, 2026, 19:00 ET Corero Network Security Chốt Hợp Đồng với 2 Nhà Khai Thác Viễn Thông Cấp 1 tại Khu Vực Châu Á - Thái Bình Dương (APAC).
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), công ty hàng đầu được công nhận trong lĩnh vực bảo vệ chống tấn công từ chối dịch vụ phân tán (DDoS) và là đơn vị tiên phong cung cấp
More news about: Corero Network Security
Jan 28, 2026, 16:16 ET CPKC announces industry veteran Gordon Trafton appointed board vice-chair
Senior Vice-President Strategic Acquisitions and Integration and as Senior Vice-President, Southern Region at CN. Prior to that, Mr. Trafton worked as CN's Vice President, Operations Integration. On CPKC's board, Mr. Trafton chairs the Risk and Sustainability Committee, serves on the Management Resources
More news about: CPKC
Jan 28, 2026, 07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease
exosomes for solid tumors, the research team has now extended this advanced platform into the highly challenging domain of the central nervous system (CNS).
More news about: China Medical University Hospital
Jan 28, 2026, 07:30 ET REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
Jan 27, 2026, 17:52 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:48 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:48 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:45 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:38 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:31 ET Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making
Conference Coverage: The fast pace of innovation in neurological diseases, such as Alzheimer's, Parkinson's, Schizophrenia, multiple sclerosis, and rare CNS disorders, makes it difficult for organizations to synthesize and interpret emerging data. DelveInsight's neurology conference coverage of the EAN
More news about: DelveInsight Business Research, LLP
Jan 27, 2026, 12:00 ET New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission
blood-brain-barrier (BBB) and/or abnormal vascularity of:the brain, spine, and associated tissues of the central nervous system (CNS);the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.For these indications, an MRI examination with
More news about: Guerbet
Jan 27, 2026, 08:46 ET The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age
54(8):475-484.Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast
More news about: Bracco Group
Jan 27, 2026, 02:00 ET The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age
54(8):475-484.Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast
More news about: Bracco Group
Jan 26, 2026, 09:30 ET Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Weinstein, CEO of Lunai Bioworks. "Our strategy is to build high-value, partner-ready programs that leverage our platform to address large, underpenetrated CNS markets."The program is supported by a Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) and is being
More news about: Lunai Bioworks Inc.